Pasar al contenido principal

NUEVOS BIOMARCADORES EN ELA: MUTACIONES SOMATICAS, NEUROINFLAMACION Y METABOLISMO DE ARN

PI17/00949

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INVESTIGACION SANITARIA ARAGON
Centro realización INSTITUTO DE INVESTIGACION SANITARIA ARAGON

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Reseña (Review)

Competing endogenous rna networks as biomarkers in neurodegenerative diseases

  • Moreno-García, L.
  • López-Royo, T.
  • Calvo, A.C.
  • Toivonen, J.M.
  • de la Torre, M.
  • Moreno-Martínez, L.
  • Molina, N.
  • Aparicio, P.
  • Zaragoza, P.
  • Manzano, R.
  • Osta, R.
Protein aggregation is classically considered the main cause of neuronal death in neurodegenerative diseases (NDDs). However, increasing evidence suggests that alteration of RNA metabolism is a key factor in the etiopathogenesis of these complex disorders. Non-coding RNAs are the major contributor to the human transcriptome and are particularly abundant in the central nervous system, where they have been proposed to be involved in the onset and development of NDDs. Interestingly, some ncRNAs (such as lncRNAs, circRNAs and pseudogenes) share a common functionality in their ability to regulate gene expression by modulating miRNAs in a phenomenon known as the competing endogenous RNA mechanism. Moreover, ncRNAs are found in body fluids where their presence and concentration could serve as potential non-invasive biomarkers of NDDs. In this review, we summarize the ceRNA networks described in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis and spinocerebellar ataxia type 7, and discuss their potential as biomarkers of these NDDs. Although numerous studies have been carried out, further research is needed to validate these complex interactions between RNAs and the alterations in RNA editing that could provide specific ceRNET profiles for neurodegenerative disorders, paving the way to a better understanding of these diseases.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Reseña (Review)

What skeletal muscle has to say in amyotrophic lateral sclerosis: implications for therapy

  • Manzano, Raquel
  • Toivonen, Janne Markus
  • Moreno-Martínez, Laura
  • de la Torre, Miriam
  • Moreno-García, Leticia
  • López-Royo,Tresa
  • Molina, Nora
  • Zaragoza, Pilar
  • Calvo, Ana Cristina
  • Osta, Rosario
Amyotrophic lateral sclerosis (ALS) is an adult onset disorder characterised by progressive neuromuscular junction (NMJ) dismantling and degeneration of motor neurons leading to atrophy and paralysis of voluntary muscles responsible for motion and breathing. Except for a minority of patients harbouring genetic mutations, the origin of most ALS cases remains elusive. Peripheral tissues, and particularly skeletal muscle, have lately demonstrated an active contribution to disease pathology attracting a growing interest for these tissues as therapeutic targets in ALS. In this sense molecular mechanisms essential for cell and tissue homeostasis have been shown to be de‐regulated in the disease. These include muscle metabolism and mitochondrial activity, RNA processing, tissue‐resident stem cell function responsible for muscle regeneration, and proteostasis that regulates muscle mass in adulthood. This review aims to compile scientific evidence that demonstrates the role of skeletal muscle in ALS pathology and serve as reference for development of novel therapeutic strategies targeting this tissue to delay disease onset and progression.